Skip to main content
Erschienen in: Langenbeck's Archives of Surgery 2/2020

05.05.2020 | Original Article

Long-term outcome of surgical resection in patients with gastroenteropancreatic neuroendocrine neoplasia: results from a German nation-wide multi-centric registry

verfasst von: Nehara Begum, Sebastian Maasberg, Andreas Pascher, Ursula Plöckinger, Thomas M. Gress, Christine Wurst, Frank Weber, Andreas Raffel, Markus Krausch, Katharina Holzer, Detlef K. Bartsch, Thomas J. Musholt, Tobias Keck, Martin Anlauf, Anja Rinke, Ulrich-Frank Pape, Peter E. Goretzki, On behalf of the German NET-Registry

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Neuroendocrine neoplasia (NEN) are rare and heterogenous tumours. Few data exist on the impact of surgical therapy.

Materials and methods

This is a retrospective analysis of prospectively collected data of gastroenteropancreatic NEN in the German NET-Registry (1999–2012). It focuses on patients without distant metastases (limited disease, LD, stage I–IIIB).

Results

Data of 2239 patients with NEN were recorded. Median age was 59 years, the gender ratio was 1:1.3 (f:m). A total of 986 patients (44%) had LD, and the 5-year survival rate (5 years) was 77% for all and 90% for patients with LD. A total of 1635 patients (73%) received a surgical therapy (1st to 6th line); the 5 and 10 ysr were 83/65% after and 59/35% without surgery for all patients (p < .001). The resection margins in the LD patients were 76%, 16%, and 3% for R0, R1 and R2, respectively. The 10 ysr was 84%, 59% and 42% for R0, R1 and R2 resections, respectively (p = .021 R0/R1, p < .001 R0/R2). The R0 resection rate was 75% for G1/G2 NET and 67% for G3 NEC.

Conclusion

The rate of complete tumour resection (R0) in LD is independent of tumour grading, and R0 resection is the key determinant of long-term survival, as demonstrated by the 10 ysr. of 84%. All NEN patients with limited disease should be considered for operation, if possible, as the best 10-year survival is shown after an R0 resection.
Literatur
1.
Zurück zum Zitat Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez del Prado M, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Benavent-Viñuelas M, Monleon A, Salazar R (2010) Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21(9):1794–1803CrossRef Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez del Prado M, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Benavent-Viñuelas M, Monleon A, Salazar R (2010) Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21(9):1794–1803CrossRef
3.
Zurück zum Zitat Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072CrossRef Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072CrossRef
4.
Zurück zum Zitat Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG (2001) Epidemiology and survival in patients with carcinoid disease in the Netherlands. An epidemiological study with 2391 patients. Ann Oncol 12(9):1295–1300CrossRef Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG (2001) Epidemiology and survival in patients with carcinoid disease in the Netherlands. An epidemiological study with 2391 patients. Ann Oncol 12(9):1295–1300CrossRef
5.
Zurück zum Zitat Fitzgerald TL, Hickner ZJ, Schmitz M, Kort EJ (2008) Changing incidence of pancreatic neoplasms. A 16-year review of nationwide tumor registry. Pancreas 37:134–138CrossRef Fitzgerald TL, Hickner ZJ, Schmitz M, Kort EJ (2008) Changing incidence of pancreatic neoplasms. A 16-year review of nationwide tumor registry. Pancreas 37:134–138CrossRef
6.
Zurück zum Zitat Hallet J, Law C, Cukier M, Saskin R, Liu N, Singh S (2015) Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 121:589–597CrossRef Hallet J, Law C, Cukier M, Saskin R, Liu N, Singh S (2015) Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 121:589–597CrossRef
8.
Zurück zum Zitat Hallet J, Law CHL, Karanicolas PJ, Saskin R, Liu N, Singh S (2015) Rural-urban disparities in incidence and outcomes of neuroendocrine tumors: a population-based analysis of 6271 cases. Cancer 121:2214–2221CrossRef Hallet J, Law CHL, Karanicolas PJ, Saskin R, Liu N, Singh S (2015) Rural-urban disparities in incidence and outcomes of neuroendocrine tumors: a population-based analysis of 6271 cases. Cancer 121:2214–2221CrossRef
9.
Zurück zum Zitat Begum N, Maasberg S, Plöckinger U, Anlauf M, Rinke A, Pöpperl G, Lehnert H, Izbicki JR, Krausch M, Vashist YK, Raffel A, Bürk CG, Hoffmann J, Goretzki P, Pape UF, Weitere Vertreter des deutschen NET-Registers (2012) Neuroendocrine tumours of the GI tract--data from the German NET registry. Zentralbl Chir 139(3):276–283. https://doi.org/10.1055/s-0032-1315199 CrossRefPubMed Begum N, Maasberg S, Plöckinger U, Anlauf M, Rinke A, Pöpperl G, Lehnert H, Izbicki JR, Krausch M, Vashist YK, Raffel A, Bürk CG, Hoffmann J, Goretzki P, Pape UF, Weitere Vertreter des deutschen NET-Registers (2012) Neuroendocrine tumours of the GI tract--data from the German NET registry. Zentralbl Chir 139(3):276–283. https://​doi.​org/​10.​1055/​s-0032-1315199 CrossRefPubMed
10.
Zurück zum Zitat Klith G, Couvelard A, Perren A et al (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 90:162–166CrossRef Klith G, Couvelard A, Perren A et al (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 90:162–166CrossRef
11.
Zurück zum Zitat Boninsegna L, Panzuto F, Partelli S (2012) Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer 48:1608–1615CrossRef Boninsegna L, Panzuto F, Partelli S (2012) Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer 48:1608–1615CrossRef
12.
Zurück zum Zitat Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Körner M, Lopes JM, McNicol A, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B, all other Frascati Consensus Conference participants, European Neuroendocrine Tumor Society (ENETS) (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449(4):395–401CrossRef Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Körner M, Lopes JM, McNicol A, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B, all other Frascati Consensus Conference participants, European Neuroendocrine Tumor Society (ENETS) (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449(4):395–401CrossRef
13.
Zurück zum Zitat Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol A, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2007) TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451(4):757–762CrossRef Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol A, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2007) TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451(4):757–762CrossRef
14.
Zurück zum Zitat Sobin LH, Gospodarowicz MK, Wittekind C (eds) (2009) TNM classification of malignant tumours, Seventh edn. Wiley-Blackwell, Oxford Sobin LH, Gospodarowicz MK, Wittekind C (eds) (2009) TNM classification of malignant tumours, Seventh edn. Wiley-Blackwell, Oxford
15.
Zurück zum Zitat Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) (2010) WHO classification of tumours of the digestive system, Fourth edn. International Agency for Research on Cancer (IARC), Lyon Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) (2010) WHO classification of tumours of the digestive system, Fourth edn. International Agency for Research on Cancer (IARC), Lyon
17.
Zurück zum Zitat Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler MW, Capella C, Caplin M, Couvelard A, Doglioni C, Delle Fave G, Fischer L, Fusai G, de Herder WW, Jann H, Komminoth P, de Krijger RR, la Rosa S, Luong TV, Pape U, Perren A, Ruszniewski P, Scarpa A, Schmitt A, Solcia E, Wiedenmann B (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104(10):764–777. https://doi.org/10.1093/jnci/djs208 CrossRefPubMed Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler MW, Capella C, Caplin M, Couvelard A, Doglioni C, Delle Fave G, Fischer L, Fusai G, de Herder WW, Jann H, Komminoth P, de Krijger RR, la Rosa S, Luong TV, Pape U, Perren A, Ruszniewski P, Scarpa A, Schmitt A, Solcia E, Wiedenmann B (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104(10):764–777. https://​doi.​org/​10.​1093/​jnci/​djs208 CrossRefPubMed
19.
Zurück zum Zitat Steinmüller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, Lopes JM, Perren A, Nikou G, Yao J, Delle Fave GF, O'Toole D, Frascati Consensus Conference participants (2008) Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 87(1):47–62CrossRef Steinmüller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, Lopes JM, Perren A, Nikou G, Yao J, Delle Fave GF, O'Toole D, Frascati Consensus Conference participants (2008) Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 87(1):47–62CrossRef
21.
Zurück zum Zitat Norton JA, Fraker DL, Alexander HR, Gibril F, Liewehr DJ, Venzon DJ, Jensen RT (2006) Surgery increases survival in patients with gastrinoma. Ann Surg 244(3):410–419PubMedPubMedCentral Norton JA, Fraker DL, Alexander HR, Gibril F, Liewehr DJ, Venzon DJ, Jensen RT (2006) Surgery increases survival in patients with gastrinoma. Ann Surg 244(3):410–419PubMedPubMedCentral
22.
Zurück zum Zitat Partelli S, Inama M, Rinke A, Begum N, Valente R, Fendrich V, Tamburrino D, Keck T, Caplin ME, Bartsch D, Thirlwell C, Fusai G, Falconi M (2015) Long-term outcomes of surgical management of pancreatic neuroendocrine tumors with synchronous liver metastases. Neuroendocrinology 102:68–76CrossRef Partelli S, Inama M, Rinke A, Begum N, Valente R, Fendrich V, Tamburrino D, Keck T, Caplin ME, Bartsch D, Thirlwell C, Fusai G, Falconi M (2015) Long-term outcomes of surgical management of pancreatic neuroendocrine tumors with synchronous liver metastases. Neuroendocrinology 102:68–76CrossRef
23.
Zurück zum Zitat Ploeckinger U, Kloeppel G, Wiedenmann B, Lohmann R, representatives of 21 German NET Centers (2009) The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology 90:349–363CrossRef Ploeckinger U, Kloeppel G, Wiedenmann B, Lohmann R, representatives of 21 German NET Centers (2009) The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology 90:349–363CrossRef
24.
Zurück zum Zitat Rindi G, Arnold R, Bosman FT et al (2010) Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumors of the digestive system. Lyon, IARC Rindi G, Arnold R, Bosman FT et al (2010) Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumors of the digestive system. Lyon, IARC
25.
Zurück zum Zitat Sakin A, Tambas M, Secmeler S et al Factors affecting survival in neuroendocrine tumors: a 15-year single center experience. Asian Pac J Cancer Prev 19(12):3597–3603CrossRef Sakin A, Tambas M, Secmeler S et al Factors affecting survival in neuroendocrine tumors: a 15-year single center experience. Asian Pac J Cancer Prev 19(12):3597–3603CrossRef
26.
Zurück zum Zitat Niederle MB, Hackl M, Kaserer K, Niederle B (2010) Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 17:909–918CrossRef Niederle MB, Hackl M, Kaserer K, Niederle B (2010) Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 17:909–918CrossRef
28.
Zurück zum Zitat Jilesen APJ, van Eijck CHJ, in’t Hof KH et al (2016) Postoperative complications, in-hospital mortality and 5-year survival after surgical resection for patients with a pancreatic neuroendocrein tumor: a systematic review. World J Surg 40:729–748CrossRef Jilesen APJ, van Eijck CHJ, in’t Hof KH et al (2016) Postoperative complications, in-hospital mortality and 5-year survival after surgical resection for patients with a pancreatic neuroendocrein tumor: a systematic review. World J Surg 40:729–748CrossRef
29.
Zurück zum Zitat Hill JS, McPhee JT, McDade TP et al (2009) Pancreatic neuroendocrine tumors-the impact of surgical resection on survival. Cancer:741–751 Hill JS, McPhee JT, McDade TP et al (2009) Pancreatic neuroendocrine tumors-the impact of surgical resection on survival. Cancer:741–751
30.
Zurück zum Zitat Shafqat H, Ali S, Salhab M et al Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population ation population lation h and colon, surgery is seen as the Shafqat H, Ali S, Salhab M et al Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population ation population lation h and colon, surgery is seen as the
Metadaten
Titel
Long-term outcome of surgical resection in patients with gastroenteropancreatic neuroendocrine neoplasia: results from a German nation-wide multi-centric registry
verfasst von
Nehara Begum
Sebastian Maasberg
Andreas Pascher
Ursula Plöckinger
Thomas M. Gress
Christine Wurst
Frank Weber
Andreas Raffel
Markus Krausch
Katharina Holzer
Detlef K. Bartsch
Thomas J. Musholt
Tobias Keck
Martin Anlauf
Anja Rinke
Ulrich-Frank Pape
Peter E. Goretzki
On behalf of the German NET-Registry
Publikationsdatum
05.05.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 2/2020
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-020-01868-1

Weitere Artikel der Ausgabe 2/2020

Langenbeck's Archives of Surgery 2/2020 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.